BACKGROUND: A phase II study was conducted using concurrent paclitaxel, carboplatin, and external beam radiotherapy (RT) in patients with advanced head and neck cancer. METHODS: Forty-three patients (stage III, n = 12; stage IV, n = 31) were treated with 8 cycles of weekly paclitaxel (60 mg/m(2)), carboplatin (area under the curve [AUC] = 1), and RT (1.8 Gy daily; total dose, 66-72 Gy). Patients with initially palpable lymph nodes underwent neck dissection. RESULTS: The overall clinical response rate was 91% (65% complete, 26% partial). Severe mucositis occurred in 37 (90%) patients, necessitating hospitalization in 13 (31%) patients. With a median follow-up of 49 months, the locoregional and distant failure rates were 26% and 21%, respectively. CONCLUSIONS: Concurrent paclitaxel, carboplatin, and RT for advanced head and neck cancer results in high complete response rates. Long-term follow-up has revealed the curative potential of this regimen, though the doses used resulted in unacceptable toxicity. (c) 2007 Wiley Periodicals, Inc. Head Neck 2008.
BACKGROUND: A phase II study was conducted using concurrent paclitaxel, carboplatin, and external beam radiotherapy (RT) in patients with advanced head and neck cancer. METHODS: Forty-three patients (stage III, n = 12; stage IV, n = 31) were treated with 8 cycles of weekly paclitaxel (60 mg/m(2)), carboplatin (area under the curve [AUC] = 1), and RT (1.8 Gy daily; total dose, 66-72 Gy). Patients with initially palpable lymph nodes underwent neck dissection. RESULTS: The overall clinical response rate was 91% (65% complete, 26% partial). Severe mucositis occurred in 37 (90%) patients, necessitating hospitalization in 13 (31%) patients. With a median follow-up of 49 months, the locoregional and distant failure rates were 26% and 21%, respectively. CONCLUSIONS: Concurrent paclitaxel, carboplatin, and RT for advanced head and neck cancer results in high complete response rates. Long-term follow-up has revealed the curative potential of this regimen, though the doses used resulted in unacceptable toxicity. (c) 2007 Wiley Periodicals, Inc. Head Neck 2008.
Authors: Gregory Vlacich; Roberto Diaz; Steven W Thorpe; Barbara A Murphy; Wyndee Kirby; Robert J Sinard; Bashar Shakhtour; Yu Shyr; Patrick Murphy; James L Netterville; Wendell G Yarbrough; Anthony J Cmelak Journal: Oncologist Date: 2012-05-01
Authors: Irina Y Dobrosotskaya; Emily Bellile; Matthew E Spector; Bhavna Kumar; Felix Feng; Avraham Eisbruch; Gregory T Wolf; Mark E P Prince; Jeffrey S Moyer; Theodoros Teknos; Douglas B Chepeha; Heather M Walline; Jonathan B McHugh; Kitrina G Cordell; P Daniel Ward; Serena Byrd; Jessica H Maxwell; Susan Urba; Carol R Bradford; Thomas E Carey; Francis P Worden Journal: Head Neck Date: 2013-07-02 Impact factor: 3.147
Authors: Muhammad Furqan; Travis P Snyders; Mohammed U Saqlain; Sarah L Mott; Douglas Laux; Anthony Snow; Carryn M Anderson; John M Watkins; Gerald H Clamon Journal: Cancer Med Date: 2019-04-09 Impact factor: 4.452